RNS Number:0459S
BioProgress PLC
13 November 2003

                BioProgress PLC ("BioProgress" or the "Company")



As disclosed in the proxy statement/prospectus of the Company dated 16 May 2003
(the "Prospectus") which formed part of the Company's AIM admission document
dated 19 May 2003, the Company has in issue equity units (Equity Units), each
consisting of 7,500 ordinary shares in the capital of the Company and six
warrants to purchase 2,500 ordinary shares each, exercisable on the terms and at
the prices set out in the Prospectus. Pursuant to the rights attaching to the
Equity Units and pursuant to the Company's obligations under the agreement and
plan of merger which was annexed to the Prospectus, the Company has today issued
436.9 Equity Units and 3,637,543 new ordinary shares of 1p each in the Company
("New Shares"). If the warrants attaching to the Equity Units issued today were
exercised in full, a further 6,553,494 new ordinary shares would be required to
be issued. The warrants are exercisable at prices of between US$ 1 and US$ 10
per share. Application has been made for the New Shares to be admitted to the
Alternative Investment Market ("AIM").



Admission of the New Shares is expected to become effective on 20 November 2003.





13 November 2003








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IOEBJBATMMMBBJJ